GLP-1 statistics 2026: how many Americans use them, prescriptions, spending and coverage

of US adults say they have ever taken a GLP-1 drug for weight loss, diabetes or another condition¹

KFF Health Tracking Poll fielded October 27 to November 2, 2025, among 1,350 adults.

of US adults say they are currently taking a GLP-1 drug, about 1 in 8¹

KFF reports current use rose 6 percentage points from its May 2024 poll.

of adults ages 50 to 64 are currently taking a GLP-1, the highest of any age group¹

Current use was 4% at ages 18 to 29, 11% at 30 to 49 and 9% at 65 and older (2025).

of women vs men report currently taking a GLP-1 drug²

KFF poll, October to November 2025.

of adults with a diabetes diagnosis are currently taking a GLP-1, and 57% have ever taken one¹

Among adults told they were overweight or obese in the past five years, 23% are current users and 34% have ever used one (2025).

of US adults reported taking a GLP-1 specifically for weight loss in 2025, up from 5.8% in early 2024³

Gallup National Health and Well-Being Index; 2025 GLP-1 figures come from surveys fielded May to June and August to September 2025.

of US adults have ever used a GLP-1 for weight loss, and 11% are currently using one for weight loss⁴

Gallup survey fielded May 28 to June 5, 2026; both figures were new highs for Gallup's measure.

US adult obesity rate in 2025, down from a record 39.9% in 2022³

Self-reported height and weight; Gallup links part of the decline to rising GLP-1 use.

of adults not taking a GLP-1 say they would be interested in taking one to lose weight¹

Interest rises to 43% among non-users told they were overweight or obese in the past five years (2025).

prescriptions for Ozempic, Mounjaro, Wegovy and Zepbound were dispensed at US retail pharmacies from January 2023 to September 2024⁵

IQVIA National Prescription Audit data. Ozempic made up 52% of these prescriptions, Mounjaro 29%, Wegovy 14% and Zepbound 5%.

of those GLP-1 prescriptions were written by primary care providers, followed by nurse practitioners at 25%⁵

IQVIA data, January 2023 to September 2024.

GLP-1 claims were filled in Medicare Part D in 2024, up from 4.8 million in 2019⁶

GLP-1 prescriptions were paid for by Medicaid in 2024, up from about 1 million in 2019⁷

GLP-1s were about 1% of Medicaid prescriptions in 2024.

increase in the number of US adolescents and young adults dispensed a GLP-1 between 2020 and 2023, from 8,722 to 60,567⁸

Ages 12 to 25, based on IQVIA prescription data.

of adults who have taken a GLP-1 got it from an online provider or website¹

76% got it from a primary care provider or specialist and 9% from a medical spa or aesthetic center (2025).

gross Medicare Part D spending on GLP-1 drugs in 2024⁶

Gross spending before manufacturer rebates; about five times the 2019 level.

of 2024 Part D GLP-1 gross spending went to Ozempic, with Mounjaro at 23%, Rybelsus at 7% and Wegovy at 1%⁶

gross Medicaid spending on GLP-1 drugs in 2024, up from about $1 billion in 2019⁷

GLP-1s accounted for over 8% of Medicaid prescription drug spending before rebates in 2024.

gross Medicaid spending per GLP-1 prescription in 2024⁷

of Eli Lilly's 2025 revenue came from its two tirzepatide brands, Mounjaro and Zepbound⁹

Worldwide 2025 revenue was $22,965 million for Mounjaro and $13,542 million for Zepbound.

of adults with overweight or obesity but without type 2 diabetes stopped their GLP-1 within one year of starting¹⁰

Retrospective study of 125,474 US adults who started liraglutide, semaglutide or tirzepatide between 2018 and 2023, using electronic health record data.

of adults with type 2 diabetes stopped their GLP-1 within one year¹⁰

of people without type 2 diabetes who stopped a GLP-1 restarted within one year, compared with 47.3% of those with type 2 diabetes¹⁰

of adults who have taken a GLP-1 say they stopped because of cost, and 13% because of side effects¹

KFF poll, 2025. 5% stopped because their condition improved.

of body weight were regained in the year after semaglutide was stopped, in the STEP 1 trial extension¹¹

Participants lost 17.3% of body weight on semaglutide over 68 weeks; net loss at week 120 was 5.6%.

of adults who have taken a GLP-1 say insurance covered at least part of the cost¹

48% had partial coverage and 22% full coverage (2025).

of GLP-1 users with health insurance say they paid the full cost themselves²

of GLP-1 users say the drugs were difficult to afford, including 55% of those with insurance²

of firms with 5,000 or more workers covered GLP-1s primarily for weight loss in 2025, up from 28% in 2024¹²

Coverage was 16% at firms with 200 to 999 workers and 30% at firms with 1,000 to 4,999 workers.

of US employers with 500 or more employees covered GLP-1 weight-loss drugs in 2025, up from 44% in 2024¹³

state Medicaid programs covered GLP-1s for obesity treatment under fee-for-service as of January 2026, down from 16 in October 2025⁷

monthly copay for eligible Medicare beneficiaries under the Medicare GLP-1 Bridge, which began July 1, 2026¹⁴

Covers Wegovy, Foundayo and Zepbound KwikPen for weight management with prior authorization.